■这项研究旨在阐明乌干达队列中对ModernamRNA-1273COVID-19疫苗的长期抗体反应,旨在为撒哈拉以南非洲地区m-RNA疫苗免疫原性的稀疏数据做出贡献。
■我们跟踪了19名年龄在18至67岁之间的参与者的抗体的发展和持久性,他们接受了两剂mRNA-1273疫苗。经过验证的酶联免疫吸附测定(ELISA)用于定量SARS-CoV-2特异性IgG,IgM,和针对刺突(S)和核蛋白(N)的IgA抗体。研究的时间范围从基线延长到一年,捕捉即时和长期的免疫反应。使用Wilcoxon检验进行统计分析,以评估抗体水平在预定间隔内的变化,其中Hochberg校正用于多重比较。
■我们的结果表明,尖峰定向IgG(S-IgG)和尖峰定向IgA(S-IgA)水平的初始显着上升,在研究期间保持升高。S-IgG浓度在加强后14天达到峰值,虽然尖峰定向IgM(S-IgM)水平是短暂的,与他们的早期反应角色保持一致。值得注意的是,加强后抗体浓度没有显著变化.先前的S-IgG状态影响了引发后的S-IgA动力学,基线S-IgG阳性个体维持较高的S-IgA反应,升压后未达到统计学差异的差异。3例突破性感染:其中2例表现出S-IgG基线血清阳性的参与者,以及一名最初对S-IgG呈血清阴性的参与者。
■总而言之,mRNA-1273疫苗引起强烈和持续的S-IgG和S-IgA抗体反应,特别是在第一次给药之后,表明长期免疫的潜力。之前的病毒暴露增强疫苗接种后的S-IgA反应相比,幼稚的个体,与先前的天真一致,后提升。加强剂量后观察到的稳定抗体水平,在很长一段时间内保持高位,没有明显的二次上升,基线暴露没有差异,表明初始疫苗接种可以充分启动免疫系统,以延长该人群的保护,由于抗体应答在加强时仍然很高,因此有可能延迟加强时间表.这一发现要求在这种人口统计学中重新评估加强剂量计划。
This study sought to elucidate the long-term antibody responses to the Moderna mRNA-1273 COVID-19 vaccine within a Ugandan cohort, aiming to contribute to the sparse data on m-RNA vaccine immunogenicity in Sub-Saharan Africa.
We tracked the development and persistence of the elicited antibodies in 19 participants aged 18 to 67, who received two doses of the mRNA-1273 vaccine. A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibodies against the spike (S) and nucleoproteins (N). The study\'s temporal scope extended from the baseline to one year, capturing immediate and long-term immune responses. Statistical analyses were performed using the Wilcoxon test to evaluate changes in antibody levels across predetermined intervals with the Hochberg correction for multiple comparisons.
Our results showed a significant initial rise in spike-directed IgG (S-IgG) and spike-directed IgA (S-IgA) levels, which remained elevated for the duration of the study. The S-IgG concentrations peaked 14 days afterboosting, while spike-directed IgM (S-IgM) levels were transient, aligning with their early response role. Notably, post-booster antibody concentrations did not significantly change. Prior S-IgG status influenced the post-priming S-IgA dynamics, with baseline S-IgG positive individuals maintaining higher S-IgA responses, a difference that did not reach statistical difference post-boost. Three instances of breakthrough infections: two among participants who exhibited baseline seropositivity for S-IgG, and one in a participant initially seronegative for S-IgG.
In conclusion, the mRNA-1273 vaccine elicited robust and persistent S-IgG and S-IgA antibody responses, particularly after the first dose, indicating potential for long-term immunity. Prior viral exposure enhances post-vaccination S-IgA responses compared to naive individuals, which aligned with the prior-naïve, post-boost. The stable antibody levels observed post-booster dose, remaining high over an extended period, with no significant secondary rise, and no difference by baseline exposure, suggest that initial vaccination may sufficiently prime the immune system for prolonged protection in this population, allowing for potential to delay booster schedules as antibody responses remained high at the time of boosting. This finding calls for a reassessment of the booster dose scheduling in this demographic.